Expert Review of Anti-infective Therapy
Revised version 24.06.2020

Editorial

Porphyromonas gingivalis infection may contribute to systemic and intracerebral amyloid-beta: Implications for Alzheimer's disease onset

Abstract

The microbiota of "chronic" periodontitis, particularly *Porphyromonas gingivalis*, have been implicated in Alzheimer's disease (AD) because this bacterium has a range of enzymes (cathepsin B and gingipains) that are shown to interact with the amyloid precursor protein (APP) and neuronal tau resulting in the formation of amyloid-beta (Aβ) and neurofibrillary tangles (NFTs). These two lesions remain pivotal to explaining AD pathogenesis alongside of clinical symptoms. Deposits of Aβ in the brain can start 10-20 years before the clinical symptoms of cognitive decline and the diagnosis of AD is established. It is rarely mentioned that the AD risk doubles if the individual has received a diagnosis of periodontitis for around 10 years. This editorial is a review of recent but salient literature supporting the idea that periodontal disease can contribute to a systemic Aβ pool that may enter the brain over time. In addition, intracerebral production of Aβ can be initiated by *P. gingivalis*, which occurs via host and bacterially derived cathepsin B acting as β-secretase to process the APP via the amyloidogenic pathway yielding $A\beta_{3\text{-}42}$. These findings support a systemic and an intracerebral Aβ contribution from "chronic" periodontitis in subsequent AD development.

Keywords Inflammation; microbiota; periodontitis; systemic; amyloid; $A\beta_{3\text{-}42}$; cathepsin B;

Introduction

Generalized ("chronic") periodontitis, a common inflammatory disease affecting the supporting tissues of teeth, has been associated with several systemic diseases, e.g. cardiovascular diseases, diabetes, adverse pregnancy outcomes, rheumatoid arthritis, respiratory diseases, and Alzheimer's disease (AD).[1-7] Bacteria of the periodontal pocket can spread through the blood stream, which is the common but not the only way of systemic bacterial dissemination in periodontitis.[8] Dental treatment, tooth brushing, flossing, chewing, and use of tooth-picks in a patient with periodontitis will release a bacteremia.[9] This can occur several times during the day and has been estimated to last for up to 3 hours.[10] Tooth-related bacteremia contains a wide spectrum of bacteria[11] among which the Gram-negative anaerobic rod *Porphyromonas gingivalis* seems to have a key role in the adult form of generalized periodontitis.[12,13]

A plethora of studies firmly place *P. gingivalis* but not its companion species (for example *Tannerella forsythia* and *Treponema denticola* in the red complex[13]) as a risk factor for AD. This is because *P. gingivalis* is adept at modifying the peripheral and intracerebral immune responses.[14-16] Furthermore, this bacterium has a range of enzymes including cathepsin B[17] and gingipains[18] that are respectively shown to interact with the amyloid precursor protein (APP) and neuronal tau resulting in the formation of amyloid-beta (Aβ) and neurofibrillary tangles (NFTs),[19,20] which are the cardinal hallmarks of AD. Prospective, retrospective population-based and nested control studies have shown that the risk of developing the sporadic form of AD doubles when periodontal disease persists for about ten years.[21-23] This is evident from the fact that a large section of individuals who go on to developing clinical AD also suffers from periodontitis.

Brain inflammation, characterized by increased activation of microglia and astrocytes, increases during aging and is a key feature of AD.[24] This has been explained in terms of the hallmark lesions of AD, which are $A\beta_{40/42}$ extracellular deposits in the form of plaques and hyperphosphorylated tau protein associating with intraneuronal lesions called NFTs. Accumulation of Aβ plaques results from the proteolytic cleavage of the APP by β- and γ-secretase enzymes.[25,26] These secretases are different in AD driven by bacterial infections compared to the classically described site-specific secretases in the mutated APP of AD.[27, 28] Similarly, toxic proteases from *P. gingivalis* called gingipains have been identified in the brain of AD patients, and the levels correlated with tau and ubiquitin pathology.[15]

Aβ is classically believed to be produced by neurons within the AD brain irrespective of the trigger that causes its release. However, this view is changing, as some researchers believe the peripheral/systemic Aβ pool is also a contribution from platelets, skeletal muscle cells, skin fibroblasts, and monocyte/macrophages[29-31] and this has implications for AD pathogenesis over time. Production of inflammagens such as gingipains and lipopolysaccharide (LPS) secreted by *P. gingivalis* also occurs in the periodontal pocket where inflammatory macrophages are reported to bear Aβ.[32] Gil-Montoya et al.[33] have reported increased plasma $A\beta_{1-42}$ levels in individuals who have severe periodontal disease. Thus Leira et al.[34] found when experimental periodontitis was induced in Sprague-Dawley rats, a strong positive correlation between alveolar bone loss and $A\beta_{1-40}$ serum levels at 7 days ($r = 0.695$, $P = 0.012$) and with serum $A\beta_{1-42}$ concentrations at 21 days ($r = 0.968$, $P = 0.002$). Taken together, Aβ also being generated peripherally in platelets, skin fibroblasts and skeletal muscles [29, 30] may enter the circulating blood.[31] The present editorial aims to discuss whether *P. gingivalis* can contribute to systemic and intracerebral pools of Aβ.

P. gingivalis induces systemic Aβ production in infected mice

Nie et al.[32] recently reported that chronic, systemic *P. gingivalis* infection increased the inflammatory responses and proteins associated with Aβ-production in the liver of mice. The liver was chosen for the peripheral Aβ source in macrophages because of the general abundance of these cells.[32] Nie et al.[32] observed that *P. gingivalis* infection in mouse liver macrophages, caused a rapid production of interleukin 1-beta (IL-1β) and thereafter an intracellular accumulation of Aβ through activation of Toll like receptor 2 /nuclear factor kappaB (TLR2/NF-κB) signaling. NF-κB-dependent cathepsin B appeared crucial for cleaving pro-IL-1β and processing APP to induce the accumulation of pathogenic $A\beta_{3-42}$, which was significantly increased in liver macrophages of the *P. gingivalis*-infected mice. This original study demonstrated peripheral pools of Aβ due to periodontitis in macrophages within the periodontal tissue and in mice hepatic macrophages following *P. gingivalis* infection. In a follow-up study, Zeng et al.[17] induced systemic *P. gingivalis* infection in mice by intraperitoneal injections containing (1×10^8 CFU/mouse every three days) for three weeks. This significantly increased the expression of the advanced glycation end products (RAGE) receptor in the cluster of differentiation 31 (CD31)-positive endothelial cells. This implied that *P. gingivalis* systemic infection up-regulated RAGE expression in cerebral endothelial cells and facilitated Aβ entry into the mouse brain. Cathepsin B was suggested to be a contribution from the bacterium and the host with a critical role in regulating the NF-

κB/RAGE expression and in the processing of APP. This study further supported the Nie et al.[32] concept for the potential in systemic spread of peripheral Aβ to the brain from *P. gingivalis* infection. In a proof of concept study, Bu et al.[31] had demonstrated the plausibility of peripheral Aβ entry to the brain being facilitated by the RAGE receptor within cerebral endothelial cells.[17] An alternative mode of peripheral Aβ entry into the brain is via macrophages of the lymphatic system.[35]

Another focus of Nie and colleagues[32] was $A\beta_{1-42}$, which is classically considered as the toxic form of Aβ. They observed that $A\beta_{3-42}$ (Fig. 1) not only occurred earlier but was also two-fold higher than $A\beta_{1-42}$ in the AD brain.[32] In AD, Cathepsin B stimulated intracellular production of Aβ in the brain, including the $A\beta_{3-42}$. Interestingly, $A\beta_{3-42}$ following *P. gingivalis*-infection in mice generated IL-1β, which is a proinflammatory cytokine.[32] IL-1β, participated in increasing the *in vivo* levels of $A\beta_{3-42}$ in the hepatic macrophages of *P. gingivalis*-infected mice and *in vitro P. gingivalis*-infected macrophages. Furthermore, $A\beta_{3-42}$ was induced by *P. gingivalis* infection, which had caused significant death of macrophages and reduced their phagocytic capacity compared to that of $A\beta_{1-42}$, suggesting $A\beta_{3-42}$ is very toxic. $A\beta_{3-42}$ was also detected exclusively in the AD brain, and this corroborates with the significantly more toxic form than $A\beta_{1-42}$.[32] This study agreed with that of Leira et al.[34] who reported that LPS from *P. gingivalis* increased Aβ protofibrils in the serum of rats. After experimental periodontitis had been induced in male Sprague-Dawley rats it caused an acute elevation of $A\beta_{1-40}$ in serum that lasted during the whole experiment. $A\beta_{1-42}$ peptide levels however, peaked at the end of the study.

P. gingivalis also generates Aβ in the periodontium and within the brain

Systemically produced Aβ probably occurs in addition to locally generated Aβ in the periodontium and in the brain induced by *P. gingivalis*. As mentioned, Leira et al.[34] found a strong positive correlation between alveolar bone loss and $A\beta_{1-40}$ serum levels at 7 days ($r = 0.695$, $P = 0.012$) and with serum $A\beta_{1-42}$ concentrations at 21 days ($r = 0.968$, $P = 0.002$). Intracerebral production of Aβ generated by *P. gingivalis* has been seen in the brain of experimental wild type animals and with AD transgenes.[19, 30-32] Ilievski et al.[19] found that chronic oral application of *P. gingivalis* to wild type mice resulted in deposition of extracellular $A\beta_{1-42}$ together with neurodegeneration and intracerebral inflammation, as demonstrated previously by Poole et al.[36] Similarly, Wu et al.[37] found that chronic exposure to

LPS from *P. gingivalis* for five consecutive weeks caused learning and memory deficits together with intracellular accumulation of Aβ in neurons of middle-aged wild-type mice. Taken together, these reports suggest that *P. gingivalis* can induce both a local periodontal and a systemic Aβ production, thereby contributing to a pool of Aβ that can enter the brain facilitated by the endothelial RAGE receptor.

P. gingivalis interferes with components of the peripheral immune system aimed to defend the brain

Unexpectedly, recent research has shown that even components of the peripheral immune system, such as macrophages can participate in defending the brain from insults occurring outside the brain.[38] However, *P. gingivalis* has the ability to abolish the anaphylatoxin complement component 5a (C5a) in macrophages thereby undermining TLR2/4 immunity and degrade some of the complement receptor 1 (CR1) molecules that help clear amyloid via the spleen.[39] Whether this affects other macrophages in a similar way is not known. Further immune evasion strategies of *P. gingivalis* in relation to AD are discussed elsewhere.[40]

Concluding remarks

We have communicated that monocytes/macrophages from the periodontium and the liver may provide an additional circulating pool of unique $A\beta_{3\text{-}42}$ fragments in patients with periodontitis. Entry of *P. gingivalis* and/or its gingipains and LPS into the brain due to a defective blood-brain barrier can lead to intracerebral deposition of Aβ plaques. These findings support the notion that the adult form of generalized periodontitis via *P. gingivalis*, contributes to both an oral and hepatic cellular source of cells that add to the systemic pool of Aβ. This peptide can also be a contribution of other cell sources of peripheral organs like skin smooth cells and platelets which have the potential to transport Aβ to the brain and over time may play a role in AD pathogenesis. Deposits of Aβ in the brain can start 10-20 years before cognitive decline and the diagnosis of AD. This agrees with the timeline of at least 10 years required for periodontitis to initiate AD and emphasizes the need for meticulous dental hygiene as a feasible prophylaxis for AD.

Funding

This paper was not funded.

Declaration of interest

The authors have no relevant affiliations of financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript.

~~Conflict of interest~~

~~No conflict of interest is reported by the authors.~~

References

1. Kumar PS. From focal sepsis to periodontal medicine: A century of exploring the role of the oral microbiome in systemic disease. J Physiol 2017; 595(2): 465-76.
2. Leuckfeld I, Obregon-Whittle MV, Lund MB, Geiran O, Bjørtuft Ø, Olsen I. Severe chronic obstructive pulmonary disease: Association with marginal bone loss in periodontitis. Respir Med 2008; 102(4): 488-44.
3. Nazir MA. Prevalence of periodontal disease, its association with systemic diseases and prevention. Int J Health Sci (Qassim) 2017; 11(2): 72-80.
4. Olsen I. From the Acta Prize Lecture 2014: The periodontal-systemic connection seen from a microbiological standpoint. Acta Odontol Scand 2015; 73(8): 563-8.
5. Olsen I, Singhrao SK. Poor oral health and its neurological consequences: Mechanisms of *Porphyromonas gingivalis* involvement in cognitive dysfunction. Curr Oral Health Rep 2019; 6: 120-9.
6. Olsen I, Singhrao SK, Potempa J. Citrullination as a plausible link to periodontitis, rheumatoid arthritis, atherosclerosis and Alzheimer's disease. J Oral Microbiol 2018; 10(1): 1487742.
7. Papapanou PN. Systemic effects of periodontitis: Lessons learned from research on atherosclerotic vascular disease and adverse pregnancy outcomes. Int Dent J 2015; 65(6): 283-91.

8. Olsen I, Singhrao SK. Can oral infection be a risk factor for Alzheimer's disease? J Oral Microbiol 2015; 7: 29143.
9. Olsen I. Update on bacteraemia related to dental procedures. Transfus Apher Sci 2008; 39: 173–8.
10. Tomás I, Diz P, Tobias A, Scully C, Donos N. Periodontal health status and bacteraemia from daily oral activities: Systematic review/meta-analysis. J Clin Periodontol 2012; 39: 213–28.
11. Bahrani-Mougeot FK, Paster BJ, Coleman S, Ashar J, Barbuto S, Lockhart PB. Diverse and novel oral bacterial species in blood following dental procedures. J Clin Microbiol 2008; 46(6): 2129-32.
12. Hajishengallis G, Darveau RP, Curtis MA. The keystone-pathogen hypothesis. Nat Rev Microbiol 2012; 10(10): 717–25. * of interest. Paper describes why *P. gingivalis* is considered a keystone pathogen in periodontitis.
13. Socransky SS, Haffajee AD, Cugini MA, Smith C, Kent RL Jr. Microbial complexes in subgingival plaque. J Clin Periodontol 1998; 25(2): 134–44.* of interest. Paper describes microbial complexes in periodontitis, including the red one.
14. Beydoun MA, Beydoun HA, Hossain S, El-Hajj ZW, Weiss J, Zonderman AB. Clinical and bacterial markers of periodontitis and their association with incident all-cause and Alzheimer's disease dementia in a large national survey. J Alzheimer's Dis 2020; doi: 10.3233/JAD-200064.
15. Dominy SS, Lynch C, Ermini F, Benedyk M, Marczyk A, Konradi A, Nguyen M, et al. *Porphyromonas gingivalis* in Alzheimer's disease brains: Evidence for disease causation and treatment with small-molecule inhibitors. Sci Adv 2019; 5(1): eaau3333. ** of considerable interest. Paper shows evidence for disease causation by *P. gingivalis* in AD.
16. Poole S, Singhrao SK, Kesavalu L, Curtis MA, Crean SJ. Determining the presence of periodontopathic virulence factors in short-term postmortem Alzheimer's disease brain tissue. J Alzheimers Dis 2013; 36: 665-77.
17. Zeng F, Liu Y, Huang W, Qing H, Kadowaki T, Kashiwazaki H, Ni J, et al. Receptor for advanced glycation end products up-regulation in cerebral endothelial cells mediates cerebrovascular-related amyloid β accumulation after *Porphyromonas gingivalis* infection. J Neurochem 2020; doi: 10.1111/jnc.15096. Online ahead of print. ** of considerable interest. Paper shows how *P. gingivalis* can contribute both systemic and to

intracerebral Aβ accumulation in the brain. Also first paper to report that *P. gingivalis* has cathepsin B activity.

18. Potempa J, Pike R, Travis J. The multiple forms of trypsin-like activity present in various strains of *Porphyromonas gingivalis* are due to the presence of either Arg-gingipain or Lys-gingipain. Infect Immun 1995; 63(4): 1176–82.
19. Ilievski V, Zuchowska PK, Green SJ, Toth PT, Ragozzino ME, Le K, Aljewari HW, et al. Chronic oral application of a periodontal pathogen results in brain inflammation, neurodegeneration and amyloid beta production in wild type mice. PLoS One 2018; 13(10): e0204941. * of interest. Paper describes how chronic application of *P. gingivalis* can cause AD in mice.
20. Haditsch U, Roth T, Rodriguez L, Hancock S, Cecere T, Nguyen M, Arastu-Kapur S, et al. Alzheimer's disease-like neurodegeneration in *Porphyromonas gingivalis* infected neurons with persistent expression of active gingipains. J Alzheimer's Dis 2020; 75: 1361–76.
21. Chen C-K, Wu Y-T, Chang Y-C. Association between chronic periodontitis and the risk of Alzheimer's disease: a retrospective, population-based, matched-cohort study. Alzheimers Res Ther 2017; 9(1): 56 doi: 10.1186/s13195-017-0282-6.
22. Lin JW, Chang CH, Caffrey JL. Feature article: Examining the association between oral health status and dementia: A nationwide nested case-controlled study. Exp Biol Med (Maywood) 2020; 245(3): 231-44.
23. Sparks Stein P, Steffen MJ, Smith C, Jicha G, Ebersole JL, Abner E, Dawson D 3rd. Serum antibodies to periodontal pathogens are a risk factor for Alzheimer's disease. Alzheimers Dement 2012; 8: 196–203.
24. Boche D, Perry VH, Nicoll JAR. Review: Activation patterns of microglia and their identification in the human brain. Neuropathol Appl Neurobiol 2013; 39: 3–18.
25. Penke B, Bogár F, Paragi G, Gera J, Fülöp L. Key peptides and proteins in Alzheimer's disease. Curr Protein Pept Sci 2019; 20(6): 577-599.
26. Xia W. Amyloid metabolism and secretases in Alzheimer's disease. Curr Neurol Neurosci Rep 2001; 1(5): 422-427.
27. Hook G, Hook V, Kindy M The cysteine protease inhibitor, E64d, reduces brain amyloid-beta and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, beta-secretase activity. J Alzheimers Dis 2011; 26: 387-408.

28. Singhrao SK, Olsen I. Assessing the role of *Porphyromonas gingivalis* in periodontitis to determine a causative relationship with Alzheimer's disease. J Oral Microbiol 2019; 11(1): 1563405.

29. Evin G, Zhu A, Holsinger RM, Masters CL, Li QX. Proteolytic processing of the Alzheimer's disease amyloid precursor protein in brain and platelets. J Neurosci Res 2003; 74: 386-92.

30. Kuo YM, Kokjohn TA,Watson MD,Woods AS, Cotter RJ, ~~LI~~Sue LI, Kalback WM, et al. Elevated abeta42 in skeletal muscle of Alzheimer disease patients suggests peripheral alterations of AbetaPP metabolism. Am J Pathol 2000; 156: 797-805.

~~30.~~31. Bu X-L, Xiang Y, Jin W-S, Wang J, Shen L-L, Huang Z-L, Zhang K, et al. Blood-derived amyloid-β protein induces Alzheimer's disease pathologies. Mol~~ecular~~ Psychiatry 2018; 23: 1948–56. ** Demonstration of systemic human Aβ from an Alzheimer's disease transgenic mouse entering the brain of a wild type mouse following parabiosis.

~~31.~~32. Nie R, Wu Z, Ni J, Zeng F, Yu W, Zhang Y, Kadowaki T, et al. *Porphyromonas gingivalis* infection induces amyloid-β accumulation in monocytes/macrophages. J Alzheimers Dis 2019; 72: 479-94. ** of considerable interest. Original paper describes -Aβ in macrophages and can constitute a pool transferred to the brain through the blood.

~~32.~~33. Gil-Montoya JA, Barrios R, Santana S, Sanchez-Lara I, Pardo CC, Fornieles-Rubio F, Montes J, et al. Association between periodontitis and amyloid β peptide in elderly people with and without cognitive impairment. J Periodontol 2017; 88:1051-8.

~~33.~~34. Leira Y, Iglesias-Rey R, Gómez-Lado N, Aguiar P, Campos F, D'Aiuto F, Castillo J, et al. *Porphyromonas gingivalis* lipopolysaccharide-induced periodontitis and serum amyloid-beta peptides. Arch Oral Biol 2019; 99: 120-5. ** of considerable interest. Paper describes how *P. gingivalis* infection in the periodontal pocket can contribute to systemic spread of amyloid-beta peptides.

35. ~~35.~~ Da Mesquita S, Louveau A, Vaccari A, Smirnov I, Cornelison RC, Kingsmore KM, Contarino C, et al. Functional aspects of meningeal lymphatics in ageing and Alzheimer's disease. Nature 2018; 560(7717): 185-91.

36. Poole S, Singhrao SK, Chukkapalli S, Rivera M, Velsko I, Kesavalu L, Crean SJ. Active invasion of *Porphyromonas gingivalis* and infection-induced complement activation in ApoE$^{-/-}$ mice brains. J Alzheimers Dis 2015; 43(1): 67-80.

37. ~~37.~~ Wu Z, Ni J, Liu Y, Teeling JL, Takayama F, Collcutt A, Ibbett P, et al. Cathepsin B playsa critical role in inducing Alzheimer's disease-like phenotypes following chronic systemic exposure to lipopolysaccharide from *Porphyromonas gingivalis* in mice. Brain Behav Immun 2017; 65:350-61.

38. Jevtic S, Sengar AS, Salter MW, McLaurin JA. The role of the immune system in Alzheimer disease: Etiology and treatment. Ageing Res Rev 2017; 40: 84-94.

39. Hajishengallis G. Immune evasion strategies of *Porphyromonas gingivalis*. J Oral Biosci 2011; 53(3): 233-40. * of interest. Mechanisms for immune evasion are explained for *P. gingivalis.*

40. Olsen I, Singhrao SK. Is there a link between genetic defects in the complement cascade and *Porphyromonas gingivalis* in Alzheimer's disease? J Oral Microbiol 2019; 12(1): 1676486.

Figure legend

Fig. 1 summarizes the Nie et al.[32] vision as interpreted by Olsen and Singhrao for the contribution to AD of peripheral pools of Aβ, specifically $A\beta_{3\text{-}42}$. It is generated by *P. gingivalis* (*Pg*) oral infection that eventually reaches the liver and the brain. The proposed signaling pathway (TLR2,4/NF-κB) is also indicated where it is likely to act liberating interleukin-1β (IL-1β) cytokine that facilitates the amyloid precursor protein cleavage of Aβ via secretase enzymes, one of which is cathepsin B. The low-density lipoprotein receptor-related protein 1 (LRP1) is the receptor for Aβ transport from the brain to the peripheral blood. The Aβ from the systemic circulation can enter the brain using the advanced glycation end products (RAGE) receptor. Nie et al.[32] have shown Aβ within the gingival tissues of periodontitis patients and in the liver of middle-aged mice after chronic systemic *P. gingivalis* infection, thereby contributing to the peripheral pools of Aβ. Some researchers believe the peripheral Aβ also comes from platelets, skeletal muscle cells, skin fibroblasts, and monocyte/macrophages. The implications of the peripheral Aβ is that it can also enter the brain and contribute to AD pathology as shown by Bu et al.[31]